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EFFECTS ON LIPID METABOLISM OF METFORMIN AND TROGLITAZONE IN 
PATIENTS WITH TYPE 2 DIABETES MELLITUS 
INGI LEE, DAVID G. MAGGS, DAVID KATZ, GERALYN R. SPOLLETT, STEPHANIE L. 
PAGE, FRANCES S. RIFE, and SILVIO E. INZUCCHI, Section of Endocrinology, Department 
of Medicine, Yale University School of Medicine, New Haven, CT 
Biguanides and the thiazolidinediones (TZDs) have distinct anti-hyperglycemic 
mechanisms of action. Both classes also influence lipid metabolism but have not been adequately 
compared. We measured the effects on lipid parameters of metformin (M), a biguanide, and 
troglitazone (T), a TZD, alone and in combination (MT), in 27 type 2 diabetic subjects. Random 
assignment was made to either M (1000 mg BID; n=15) orT (400 mg QD; n=12) for 3 mo. 
Baseline characteristics were similar between groups: mean age 53.4 years, HbAlc 9.5%, and 
BMI 33.7 kg/m2. After 3 mo. of M or T, subjects were placed on MT (n=23) for another 3 mo. 
There was an insignificant rise in HDL-C with M or T (+6%) and an additive effect with 
MT (+12%, p<.01). M decreased LDL-C by 7.5% (p=.04), T insignificantly increased levels 
(+8.1%), and MT had a neutral effect. Both M (-15.3%) and T (-16.4%) insignificantly reduced 
fasting (f-) TG; MT decreased f-TG by 27.0% (p<.01). A similar pattern was seen on 
postprandial (pp-) TG (M, -9.8% (p=NS); T, -9.7% (p=NS); MT, -15.1% (p=.006)). M did not 
affect f-FFA, whereas there was a reduction with T (-30.0%, p=.03), partially offset by MT 
(-17.3%, p<0.01). In contrast, both agents decreased pp-FFA, with T having a greater effect (M, 
-32.7% (pc.Ol); T, -48.7% (p=.001)), and little evidence for additive effect (-53%, p<.0001). 
The effects of MT on HDL-C, f-TG, and pp-TG seem to be additive, while their effects 
on LDL-C appear offsetting. T elicits a clear suppression of both f-FFA and pp-FFA, whereas M 
does not affect f-FFA and induces a less potent suppression of pp-FFA. In combination, M 
attenuates T's f-FFA effects, and there is only minimal additive benefit on pp-FFA. Overall, both 
agents have generally favorable, although differing, effects on lipid metabolism, with only some 
synergy demonstrated in combination. 
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INTRODUCTION 
Prevalence and Pathophysiology of Type 2 Diabetes Mellitus 
Diabetes mellitus (DM) is a serious and common health problem. In the US alone, 16 
million individuals are affected by DM; approximately 90% of these patients have type 2 DM 
(T2DM) (1). As the number of affected patients continues to increase, the National Health and 
Nutrition Examination Survey states that diabetes will become the most common chronic disease 
in this country (1). The national cost of treating diabetes as well as its complications (DM is the 
leading cause of blindness and renal failure) accounts for 1/6 of all health care expenditures (1). 
Intrinsic genetic factors contribute significantly to the pathogenesis of this disease. DM 
is found more often within certain ethnic groups including Hispanics, African Americans, Pacific 
Islanders, and Native American Indians. Twin studies have also shown that monozygotic twins 
have a twofold or greater concordance as compared to dizygotic twins (2). Though researchers 
have sought to isolate individual candidate genes or clusters of genes, none have been found, 
suggesting that DM involves multiple defects in various genes. Acquired factors including 
increasing age, visceral obesity, and physical inactivity have also been correlated with the 
development and progression of this disease. 
T2DM is defined by the presence of peripheral insulin resistance and non-autoimmune 
impaired insulin secretion. It begins with a compromise in insulin action. Peripheral insulin 
resistance occurs most notably in skeletal muscle and adipose tissue, resulting in decreased 
glucose disposal. Unimpaired glucagon secretion coupled with hepatic insulin resistance results 
in elevated basal hepatic glucose output. Adipocytes release free fatty acids (FFA), which along 
with glucose, are transported to the liver for triglyceride (TG) synthesis. TG becomes an 
alternative energy source for tissues such as muscle, thereby conserving glucose for the central 
nervous system. Not only is plasma glucose and FFA elevation a result of insulin resistance, but 
each also independently exacerbates insulin resistance (“glucotoxicity”, “lipotoxicity”). FFA 
oxidation also further stimulates gluconeogenesis in the liver. Pancreatic (3 cell hyperplasia 

occurs to increase insulin output. With worsening insulin resistance, however, the level of 
hyperinsulinemia becomes relatively insufficient, resulting in mild hyperglycemia, initially 
detected in the postprandial setting. (3 cell dysfunction soon follows. The decreased insulin 
response to glucose eventually results in elevated fasting blood sugar levels. The etiology of (3 
cell dysfunction is unknown but suspected etiologies include genetically programmed failure, 
glucotoxicity, and/or lipotoxicity. 
Diabetic Complications 
Microvascular complications 
Patients with T2DM are at a higher risk of developing microvascular and macrovascular 
complications compared to those unaffected by the disease. Up to 20% of patients with T2DM 
are found to have retinopathy and 7-8% are found to have neuropathy at the time of clinical 
diagnosis (3). The incidence of microvascular complications then rises as the duration of T2DM 
increases. Approximately 9% of previously unaffected patients develop neuropathy, 
nephropathy, and/or retinopathy within 9 years of diagnosis (4). 
The Diabetes Control and Complications Trial (DCCT), a large prospective multicenter 
study of type 1 diabetics, was the first to demonstrate the causal role of hyperglycemia in 
microvascular complications and thus, establish the importance of strict glucose control in these 
patients (5). As expected, the Kumamoto Study (6), the Veteran Affairs Cooperative Study (7), 
and the United Kingdom Prospective Diabetes Study (UKPDS) (8) all went on to further 
demonstrate that type 2 diabetics would similarly benefit from aggressive glucose control. 
Macrovascular complications 
Although microvascular complications increase morbidity, macrovascular complications 
take the greater toll on T2DM patients. Atherosclerosis accounts for 80% of the mortality rate, 
with cardiovascular disease (CVD) being the number one cause of death in these patients (9). 
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Atherosclerosis-related morbidity, including coronary artery disease (CAD), stroke, and 
peripheral vascular disease (PVD) is also 2.5 times higher in diabetic men and 3.5-4.5 times 
higher in diabetic women than in their non-diabetic counterparts (10, 11, 12). 
The main goal of current diabetes treatment is to strictly control glucose levels. Although 
this has been shown to benefit microvascular complications, its role on macrovascular 
complications has not been fully supported. A Finnish study showed that elevated levels of 
glycosylated hemoglobin (HbAlc) may mediate CVD in elderly diabetics through the formation 
of advanced glycation end products in vessel walls (13). A number of other theories have linked 
the genesis of atherosclerosis to endothelial dysfunction, or frequently coexisting hypertension 
and hyperlipidemia. 
Interventional studies have yielded interesting yet inconclusive results. The Veterans 
Affairs Cooperative Study (7) and the UKPDS (8) both found insignificant differences in 
macrovascular complications between their intensively treated and conventionally treated groups. 
When the UKPDS subgroups were further analyzed, however, researchers found that the group 
intensively treated with metformin had a significant 39% reduction in the incidence of myocardial 
infarction (MI) compared to patients treated conventionally with diet or intensively with 
sulfonylureas or insulin. This finding raised the possibility that different diabetic agents may 
have varying effects on macroangiopathy. The cardiovascular protective effect of metformin, 
however, was lost for unexplained reasons when it was used in combination with sulfonylureas. 
Since meticulous control of diabetic hyperglycemia has not been consistently effective in 
combating macroangiopathy, other etiologies have been studied. Insulin resistance and the 
resultant hyperinsulinemia may be key factors. 
Insulin is a growth factor, which theoretically, accelerates atherogenesis through 
vasculature smooth muscle cell and connective tissue proliferation, as well as increased platelet 
adhesiveness (14). Hyperinsulinemia has been predictive for CVD in non-diabetic patients in the 
Helsinki Policemen Study (15), the Paris Prospective Study (16), and the Quebec Cardiovascular 
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Study (17). Second, insulin resistance and hyperinsulinemia are often found in conjunction with 
other cardiovascular risk factors, such as visceral obesity, impaired glucose tolerance or diabetes, 
hypertension, aging, impaired fibrinolysis with increased levels of plasminogen activator inhibitor 
(PAI-1), and dyslipidemia (18). When present alone, each component poses a risk factor for 
CVD. Since many components are often present simultaneously [known as the insulin resistance 
syndrome (IRS)], they may synergistically increase the risk for macrovascular complications. 
Insulin resistance may, in fact, be an important causal contributor to the development of 
its associated features, including the CVD risk factor, diabetic dyslipidemia. Plasma FFA levels 
increase as adipocytes become resistant to the anti-lipolytic effects of insulin. Elevated FFA, then 
in turn, contribute to the decline in (3 cell function. Additionally, FFA coupled with high levels of 
glucose, as seen in T2DM patients, provide the main substrates necessary for TG-rich very low 
density lipoprotein (VLDL-C) production by the liver. Lipoprotein lipase (LPL), which 
hydrolyzes chylomicrons and VLDL-C to higher density lipoproteins, is also regulated by insulin. 
Insulin resistance renders this enzyme less effective. This combined decrease in VLDL-C 
clearance in conjunction with elevated VLDL-C production results in the most common lipid 
abnormality present in diabetic patients, hypertriglyceridemia (19, 20, 21). Hypertriglyceridemia, 
in turn, leads to the formation of smaller, more dense LDL-C cholesterol particles (22). LDL-C 
levels are not necessarily elevated in T2DM patients, but small, dense LDL-C particles are more 
easily oxidized and therefore, more atherogenic (23, 24). HDL-C levels are decreased in these 
patients, again, secondary to decreased production, as well as hypertriglyceridemia (17). 
Treating dyslipidemia is extremely beneficial in preventing the development of CVD in 
T2DM patients. Elevated total cholesterol, LDL-C, and TG, as well as depressed HDL-C have all 
been shown to be independent risk factors for CVD (25, 26). Additionally, studies have 
suggested that diabetics may be affected more by abnormalities in the lipid metabolism than non¬ 
diabetics. The Multiple Risk Factor Intervention Trial, for example, showed that in all patients, 
elevated total cholesterol was related to mortality due to coronary heart disease (27). However, in 
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patients with a similar degree of hypercholesterolemia, diabetic males had a fourfold greater risk 
for heart disease than their non-diabetic controls. 
Treatments for T2DM 
T2DM medications are primarily used to attain glucose control. Sulfonylureas, which 
stimulate the release of insulin at lower glycemic thresholds, comprised the first drug class to 
become available. Approximately 66% of patients respond to sulfonylureas, although 20% of the 
responders eventually require additional medication for adequate glucose control (28). 
Sulfonylureas generally have no effect on lipid profiles. Additionally, because they 
increase insulin levels, there is speculation that the sulfonylureas have at best, no effect, and at 
worst, may potentiate macrovascular complications. They remain, however, the most widely 
used oral anti-diabetic agents. 
Within the last decade, other agents have also become available in the US. Biguanides, 
which were temporarily available in the 1960s and 1970s, made a resurgence in 1995 when 
metformin was introduced into the US market (29). Its entry was quickly followed by other 
classes, such as the alpha glucosidase inhibitors, the thiazolidinediones (TZDs), and the non¬ 
sulfonylurea insulin secretagogues. The most interesting of these medications may be the 
biguanides and the TZDs. Both are insulin sparing agents which in addition to controlling 
glucose levels, may also have beneficial effects on CVD via their effects on diabetic 
dyslipidemia. 
Metformin, a Biguanide 
The anti-hyperglycemic effects of biguanides have been recognized since the 19th 
century. At that time, the active ingredient, guanidine, was extracted from the French lilac, 
Galega officinalis, to treat diabetic patients (30). Guanidine was later used to synthesize other 
biguanides. The first of these, phenformin, became commercially available in the US in the 
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1960s. In the 1970s, however, the drug was removed because it was found to increase the risk of 
lactic acidosis (29). 
Metformin was used for years in Europe and Canada before it became FDA- approved in 
December of 1994 (31). This biguanide has proven to be much safer than phenformin. The 
estimated incidence of lactic acidosis is .03 per 1000 patient-years of use (31). A majority of 
these cases occurred in the setting of incorrect use, for example, in patients with contraindications 
such as renal impairment. Approximately 30% of patients experience various side effects, most 
notably dose-related GI symptoms such as abdominal pain, nausea, and diarrhea (31). These 
symptoms, however, are tolerable for most, with only 5% of patients requiring discontinuation of 
the medication (32). 
The glucose and HbAlc lowering with metformin is equivalent to that of the 
sulfonylureas. Over 90% of patients initially show clinical improvement on metformin (31). 
With continued use, however, 5-10%/yr. become less responsive and eventually require 
additional medications (31). Unlike sulfonylureas, metformin does not cause hypoglycemia and 
has thus been categorized as an “anti-hyperglycemic.” 
Metformin’s mechanism(s) of action have yet to be fully elucidated. A majority of 
studies suggest that the drug primarily decreases hepatic glucose output by decreasing 
glycogenolysis and/or gluconeogenesis. The drug may also have modest effects on increasing 
insulin sensitivity of peripheral tissues (33, 34). Some studies have shown that there are similar 
declines in glucose and FFA levels. Lower FFA levels could theoretically improve glucose levels 
through the Randle cycle (35,36). Perriello et al. showed that there were similar effects in the 
suppression of hepatic glucose production, plasma FFA concentration, and rates of lipid 
oxidation, along with the increase in rates of glucose oxidation in patients treated with metformin 
(35). Meanwhile, Abbasi et al. demonstrated significant decreases in fasting and postprandial 
glucose as well as FFA. In their study, metformin resulted in a mean glucose decrease of 17% 
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while FFA decreased by 19% (30). However, not all studies have shown significant reductions in 
plasma FFA after metformin treatment (37). 
Because metformin reduces glucose levels without elevating insulin levels, there has long 
been speculation that the drug may also increase peripheral insulin sensitivity, and therefore, 
increase peripheral glucose disposal. Metformin is indeed ineffective in the absence of insulin 
(31). Studies have, however, yielded conflicting results as to whether improved peripheral 
glucose disposal is directly related to the drug or whether it is a secondary effect of improved 
glucose control (i.e. improved glucotoxicity) (37, 38, 39), lowering of FFA levels (i.e. improved 
lipotoxicity) (40), and/or changes in body weight and composition (37). Postprandial glucose 
lowering may also be facilitated by slow glucose absorption by the GI tract attributable to 
metformin (41). 
Metformin has rapidly gained popularity in part because of its additional beneficial 
effects on various cardiovascular risk factors. Experimental models in animals have shown that 
metformin alters aortic lipid metabolism, providing a basis for its possible protective effects 
against atherosclerosis (42). In the UKPDS, overweight patients treated with metformin 
monotherapy experienced significantly fewer macrovascular events than the control group and 
the groups treated with sulfonylurea or insulin (8). This benefit may be secondary to a multitude 
of factors. Metformin is an insulin sparing drug, it does not cause weight gain (43, 44), and it has 
been shown in some studies to have lipid lowering effects (Table 1). Overall, metformin appears 
to significantly lower total cholesterol, LDL-C, and TG, while modestly decreasing FFA and 
causing no significant change in HDL-C (62). Additionally, increased fibrinolytic activity and 
decreased platelet aggregation, as well as decreased blood pressure and peripheral arterial 
resistance have also been demonstrated (53). 
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TABLE 1: LITERATURE REVIEW OF THE EFFECTS ON LIPID 
METABOLISM OF METFORMIN 
Lipid Parameter Percent Change 
Total Cholesterol No significant change (40) or up to 17% 
decrease (49,51,55,58, 59, 60) 
VLDL-C No significant change (40) or up to 39% 
decrease (46, 52, 56, 57, 58) 
LDL-C No significant change (51, 61) or up to 24% 
decrease (55, 59, 60) 
HDL-C No significant change (35, 61) or up to 17% 
increase (45, 46, 51, 55) 
TG No significant change (45, 47, 48) or up to 
45% decrease (46, 49, 50, 51, 52, 53, 54, 55) 
FFA No significant change (45) or up to 17% 
decrease (35, 46) 
Troglitazone, a TZD 
TZDs comprise the other class of diabetic medications which may have beneficial CVD 
effects. In 1997, troglitazone became the first TZD introduced into the US market (28). 
Troglitazone was synthesized with an a-tocopherol moiety, similar in structure to vitamin E, in 
hopes of producing a TZD which would not only control hyperglycemia, but could also lower 
lipids via limiting lipid oxidation (63). Troglitazone was eventually removed from the US market 
by the FDA because of its link to rare idiosyncratic hepatocellular injury. New TZDs, such as 
rosiglitazone and pioglitazone, are now available with significantly safer side effect profiles. 
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Troglitazone has the same glucose lowering ability as sulfonylureas or metformin in 
diabetic patients (64). The drug is not associated with hypoglycemia, and therefore, is also 
referred to as an “anti-hyperglycemic”. Its mechanism of action is insulin sensitization, which 
primarily occurs in peripheral tissues but may also affect hepatic glucose production (65). To 
exert its effect, the drug requires the presence of insulin (66, 67). In a study by Suter et al., 25% 
of patients treated with 3 months of troglitazone (400mg QD) had no clinical response (68). 
Interestingly, these patients also had the lowest levels of insulin secretion. 
TZDs regulate insulin induced gene expression by activating various nuclear receptors of 
the peroxisome proliferator activated receptor (PPAR) family (69). PPAR-a, which is found in 
tissues such as the liver, kidney, heart, and muscle, is involved in fatty acid metabolism. The 
mechanism of action of the lipid lowering fibrates is via this particular receptor. TZDs primarily 
work via another member of the superfamily, PPAR-y, which is found in adipose tissue. It 
stimulates glucose disposal by increasing transcription of glucose transporters, GLUT1 and 
GLUT4, necessary for glucose uptake (69). Since PPARs are also found on vascular wall cells, 
theoretically, TZDs could directly affect the vasculature to prevent atherogenesis (70). Glucose 
lowering effects have also been associated with increased (3 cell responsiveness. (71). 
Like biguanides, TZDs also have multiple beneficial effects on CVD risk factors. They 
increase insulin sensitivity resulting in decreased insulin levels, perhaps even to a greater degree 
than metformin. The drug also appears to improve dyslipidemia (Table 2). Overall, review of the 
literature suggests that troglitazone may significantly decrease TG and FFA, while increasing 
total cholesterol, LDL-C, and HDL-C. The effects of troglitazone on the lipid profile appear to 
be dose dependent (71). 
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TABLE 2: LITERATURE REVIEW OF EFFECTS ON LIPID METABOLISM OF 
TROGLITAZONE 
Lipid Parameter Percent Change 
Total Cholesterol No significant change (71, 73, 77) or up to 
5.8% decrease 
LDL-C No significant change (47, 63, 77) or up to 
15.4% increase (71, 74, 75, 78) 
HDL-C No significant change (71, 75) or up to 24% 
increase (47, 73, 74, 76, 77) 
TG No significant change (71, 74, 75) or up to 32% 
decrease (47, 63, 72, 73, 76, 77) 
FFA No significant change (71) or up to 33% 
decrease (72, 73) 
TZDs have been shown to appreciably affect TG and FFA. A study by Maggs et al. 
demonstrated that varying doses of troglitazone had beneficial effects on both fasting and 
postprandial TG while higher doses were needed to significantly decrease FFA (79). The effects 
of troglitazone on TG lowering are thought to be secondary to decreased hepatic production as 
well as increased LPL activity. The role of insulin sensitization in lowering TG levels, however, 
is not entirely clear. A study by Saltiel et al. found that insulin deficient mice treated with 
troglitazone demonstrated similar decreases in TG as their insulin resistant counterparts (80), 
suggesting a direct hypolipidemic effect. The increase in LDL-C found in a majority of studies is 
of particular interest (63). Though elevated LDL-C is an independent risk factor for 
macrovascular complications, in this case, it may not be as detrimental as expected. Various 
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studies have shown that though LDL-C levels are elevated in patients using troglitazone, the ratio 
of LDL-C to HDL-C (71) or the ratio of HDL-C to total cholesterol (75) remains unchanged. 
Additionally, larger and less dense LDL-C particles have been noted in patients treated with 
TZDs (77, 78, 81). These particles may not as prone to oxidation as the smaller dense LDL-C 
particles and may therefore, be less atherogenic. 
TZDs also lower blood pressure, improve fibrinolysis, decrease platelet aggregability, 
and improve endothelial function (63). Further studies are necessary to evaluate whether these 
changes are actually associated with positive clinical outcomes. 
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STATEMENT OF PURPOSE AND HYPOTHESIS 
Macrovascular complications are a significant cause of morbidity and mortality in T2DM 
patients. Strict glucose control, which has been shown to prevent and/or forestall the 
development of microangiopathy, has had no appreciable effect on the outcome of 
macroangiopathy, resulting in a search for other etiologies, as well as preventive strategies. 
Insulin resistance and its associated clinical features have become targets of interest. 
Metformin and troglitazone are two insulin sparing diabetic agents which function via 
different mechanisms, but have comparable glucose lowering effects. Previous studies have also 
demonstrated that these two agents benefit diabetic dyslipidemia, a significant risk factor for 
CVD. However, their effects on lipid metabolism have not been adequately compared in a single 
study. 
Therefore, we conducted this study with the following aims in mind: 
1. To characterize the effects of metformin or troglitazone monotherapy on the lipid profiles 
[LDL-C, HDL-C, fasting and postprandial FFA, and fasting and postprandial TG] of 
T2DM patients. 
2. To characterize the effects of metformin and troglitazone combination therapy on the 
lipid profiles [LDL-C, HDL-C, fasting and postprandial FFA, and fasting and 
postprandial TG] of T2DM patients. 
3. To determine whether significant lipid altering effects correlate with changes in any of 
the following parameters: glucose, HbAlc, basal and clamp glucose production, or 
glucose disposal. 
We hypothesized that since insulin resistance is believed to be a causal factor of IRS, that 
overall, troglitazone will be more effective in controlling dyslipidemia than metformin. Second, 
because metformin may also have minor insulin sensitizing properties, we expect that metformin 
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and troglitazone combination therapy will be more effective in improving lipids than metformin 
or troglitazone monotherapy. 

14 
METHODS 
The Human Investigation Committee at Yale University School of Medicine reviewed 
and approved the protocol for the original study (64) as well as the use of its data for this project. 
Study Subjects 
The original study compared the anti-hyperglycemic potential as well as the mechanisms 
of action of metformin and troglitazone, when used alone and in combination. All 29 participants 
met the National Diabetes Data Group’s criteria for T2DM, with glycosylated hemoglobin values 
above the upper limit of normal and plasma C-peptide concentrations > 1.5ng/mL (.50 nmol/L) 
on diet, sulfonylurea, and/or biguanide therapy. The following patients were excluded from the 
study: pregnant females, patients with abnormal renal or hepatic function, and those with recent 
atherosclerotic events. 
Initially, patients were randomly distributed between 2 treatment groups: the metformin 
and troglitazone monotherapy groups. Both patients and investigators were aware of their 
treatment. Of the 15 patients (8 females and 7 males) who were in the metformin monotherapy 
group, 1 patient continued on his outpatient antilipid medication and was placed on a submaximal 
metformin dose as a consequence of its side effects. Of the 14 patients (8 males and 6 females) 
who were initially enrolled in the troglitazone group, data for only 12 patients (5 males and 7 
females) was available for this study. One patient continued to have glucose levels >350mg/dL 
and was therefore unable to complete 3 months of monotherapy. Meanwhile, a second patient did 
not have a substantial portion of their lipid data available. Three patients in the troglitazone 
monotherapy group were on anti-lipid medication, which remained stable during the study period. 
After the initial 3 months of metformin or troglitazone monotherapy, patients were 
invited to continue an additional 3 months of metformin and troglitazone combination therapy. 
One patient in the metformin monotherapy group declined further participation. (The patient who 
was originally on the anti-lipid medication as well as a submaximal metformin dose continued 
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into the combination phase.) In the troglitazone monotherapy group, 1 patient declined the 
invitation and 2 additional patients were unable to complete the combination phase because of 
unrelated illness. One troglitazone patient on anti-lipid medication continued into the 
combination phase. 
Study Design 
Monotherapy and Combination Therapy 
Patients were given a 2 week washout period, during which they discontinued their 
outpatient diabetes medication. They were then given either metformin lOOOmg BID or 
troglitazone 400mg QD for 3 months. (One patient received a submaximal daily metformin dose 
of 1500mg.) At month 0 and month 3, patients were admitted for an 8-hr mixed meal-tolerance 
test and a hyperinsulinemic-euglycemic clamp study. 
Patients who continued the second phase of the study were placed on metformin and 
troglitazone combination therapy for an additional 3 months. At month 6, patients were again 
admitted for their last 8-hr mixed meal-tolerance test and a hyperinsulinemic-euglycemic clamp 
study. 
A diet comprised of 50% carbohydrate, 34% fat, and 16% protein was recommended for 
all participants to maintain baseline body weight during the course of the study. 
Meal Tolerance Test 
The meal tolerance test was performed after an overnight fast. At approximately 8 AM, 
for breakfast, and again at 12 PM, for lunch, patients were given Sustacal-HC liquid formula 
meals. A fasting blood sample was drawn prior to breakfast followed by eight hourly 
postprandial blood samples drawn from an intravenous catheter placed in the antecubital vein. 
Blood samples were sent to Coming Nichols Institute where glucose, HbAlc, insulin, C-peptide, 
HDL-C, LDL-C, FFA, and TG levels were determined. 
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Hyperinsulinemic-Euglycemic Clamp Study and Resulting Measurements 
The hyperinsulinemic-euglycemic clamp study using [6,6-:H] glucose was performed the 
following day after an overnight fast (64). Gas chromatography-mass spectrometry was done at 
the Yale Stable Isotope Core Facility. The substrate and hormone measurements were 
determined as follows: 
1. Basal Endogenous Glucose Production = (f/BSA)x([enrichmentinf/enrichmentpiasma] - 1) 
f= basal [6,6-'H] glucose infusate rate (mg/min) 
BSA = body-surface area (in) 
enrichment^ = % enrichment of [6,6- H] glucose enrichment 
enrichment^^ = % of plasma [6,6-' H] glucose enrichment 
2. Glucose Disposal Rate = cEGP + GIR 
cEGP = endogenous glucose production during clamping (see below for calculation) 
GIR = Mean rate of exogenous glucose infusion from minutes 260 to 300 of the clamping period 
2 (mg/m /min) 
3. Endogenous Glucose Production During Clamping = GIR x ([enrichmentjnr/enrichmentpiasma] - 
i) 
Data Collection and Statistical Analysis 
For this project, charts collected from the original study were reviewed. Patients’ lipid 
and glucose profiles were entered into a Microsoft Excel database. Postprandial values were 
calculated as the mean of the 8 existing hourly measurements. 
To determine the effects of metformin and troglitazone, alone and in combination, on the 
lipid metabolism of patients with T2DM, statistical analysis was performed on the following 3 
distinct data sets: 
1. Patients who completed the initial 3 months were analyzed separately depending on the 
treatment group they were initially placed to directly compare the effects on the lipid 
metabolism of metformin and troglitazone when used alone. 

17 
2. Patients who completed six months were analyzed together regardless of their initial 
monotherapy group to analyze the effects on the lipid metabolism of metformin and 
troglitazone when used in combination. 
3. Patients who completed six months were analyzed separately depending on their initial 
monotherapy treatment to compare the effects of adding troglitazone to metformin 
monotherapy versus adding metformin to troglitazone monotherapy. 
Lipid parameters which were significantly affected underwent a second phase of analysis. 
Regression analysis was performed to determine whether changes in lipid levels correlated 
significantly with changes in glucose, HbAlc, basal endogenous glucose production, endogenous 
glucose production during the clamp study, and/or glucose disposal rates. 
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RESULTS 
Patient Characteristics 
The metformin and troglitazone groups had similar baseline characteristics. Fifteen 
patients, 8 women and 7 men, were included in the analysis of the metformin monotherapy group. 
This group was comprised of 12 Caucasians, 2 African Americans, and 1 patient of mixed 
African American and Native American ancestry. Ages ranged from 32 to 74 years with a mean 
age of 51±13 years, while the duration of diabetes ranged from 3 months to 14 years with a mean 
duration of 5±4 years. Prior to the start of the study, 8 patients were taking sulfonylureas, 1 was 
taking metformin, 4 were taking sulfonylurea and metformin combination therapy, and 2 were 
diet controlled. The mean body mass index (BMI) was 33.9±6.8 kg/m2. Twelve patients, 7 
women and 5 men, were included in the analysis of the troglitazone monotherapy group. This 
group was comprised of 10 Caucasians, 1 African American, and 1 patient of mixed African 
American, Native American, and Dutch ancestry. Ages ranged from 37 to 71 years old with a 
mean age of 56+12 years, while the duration of diabetes ranged from 2 months to 12 years with a 
mean duration of 3±3 years. Prior to the start of the study, 8 patients were taking sulfonylureas, 1 
was taking metformin, and 3 were diet controlled. The mean BMI was 32.7±7.4 kg/m2 (Table 3). 
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TABLE 3: BASELINE DEMOGRAPHICS OF PATIENTS WHO COMPLETED THE 
INITIAL 3 MONTHS OF MONOTHERAPY 
Patient Characteristics Metformin Monotherapy Troglitazone Monotherapy 
(N=15) (N=12) 
Age (yr) 51± 13 56112 
Race 2 African Americans (13%) 1 African American (8%) 
1 African American and 1 African American. Native 
Native American (7%) American, and Dutch (8%) 
12 Caucasians (80%) 10 Caucasians (83%) 
Gender 8 Females (53%) 7 Females (58%) 
7 Males (47%) 5 Males (42%) 
Anti-diabetic Medication(s) 8 on Sulfonylureas 8 on Sulfonylureas 
Prior to Study 1 on Metformin 1 on Metformin 
4 on Combination Therapy1 3 Diet Controlled 
2 Diet Controlled 
Duration of Diabetes (yr) 5 ±4 313 
Body Mass Index (kg/m2) 33.916.8 32.717.4 
*p>0.05 for above patient characteristics 
1Patients on combination therapy were on sulfonylureas and metformin 
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The patients in the metformin and troglitazone groups also had similar fasting lipid and 
diabetes profiles obtained at month 0 (after the washout period and prior to the start of 
monotherapy) (Table 4). 
TABLE 4: FASTING VALUES OBTAINED AT MONTH 0 AFTER THE WASHOUT 
PERIOD 
Fasting Parameter Metformin Group 
(N=15) 
Troglitazone Group 
(N=12) 
Glucose (mg/dL) 287+84 273170 
Glycosylated hemoglobin (%) 10.011.6 9.611.7 
HDL-C (mg/dL) 40.7110.1 40.6+8.0 
LDL-C (mg/dL) 122.4133.2 133.9135.0 
TG (mg/dL) 191.31118.1 228.9+161.2 
FFA (nmol/L) .871.27 .981.42 
*p>0.05 far above fasting parameters 
Monotherapy (Table 5) 
After the initial 3 months, metformin and troglitazone monotherapy had similar 
insignificant effects on HDL-C. Metformin increased HDL-C from 40.7±10.1 to 43.2± 15.1 
mg/dL (+6.0%; P=.27) while troglitazone increased levels from 40.6±8.0 to 43.1±8.7 mg/dL 
(+6.2%; P=. 14) (Figure 1). In contrast, there was a significant difference between their effects on 
LDL-C. Troglitazone increased LDL-C from 133.9+35.0 to 144.8+37.3 mg/dL (+8.1%; P=.ll), 
while metformin decreased levels from 122.4133.2 to 113.2132.5 mg/dL (-7.5%; P=.036) (Figure 
2). LDL-C lowering effects seen with metformin did not correlate with changes in glucose. 
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HbAlc, basal endogenous glucose production, endogenous glucose production during the clamp 
study, or glucose disposal rates. 
Metformin and troglitazone monotherapy did not appreciably alter fasting (Figure 3) or 
postprandial TG levels (Figure 4). Metformin decreased fasting TG by 15.3% (P=.097), from 
191.3± 118.1 to 162.0± 77.9 mg/dL, and postprandial TG by 9.8% (P=.15), from 253.2±116.6 to 
228.4±95.5 mg/dL. Similarly, troglitazone decreased fasting TG by 16.4% (P=.43), from 
229.0±161.2 to 191.31101.9, and postprandial TG by 9.7% (P=. 18), from 290.71147.9 to 
262.61128.0. 
Metformin did not affect fasting FFA (Figure 5). Levels decreased .27% (P=.96), from 
.8731.271 to .8711.227 nmol/L. Troglitazone significantly decreased fasting FFA by 30.0% 
(P=.033) from .981.42 to .691.24. This decrease correlated with changes in fasting glucose 
(R=.68; p=.016) (Figure 6). Both medications decreased postprandial FFA levels (Figure 7). 
Metformin decreased postprandial FFA levels from .391.20 to .261.13 nmol/L (-32.7%; 
P=.0091) and troglitazone decreased levels slightly more, from .371.21 to .191.10 
(-48.7%; P=.0013). Postprandial FFA lowering did not correlate with any changes in the glucose 
parameters. 
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Combination Therapy (Table 6) 
Three months of metformin and troglitazone combination therapy significantly 
increased HDL-C by 12% (P=.0044), from 40.4±9.1 to 45.3+12.8 mg/dL (Figure 1). There was 
no correlation between the HDL-C increase and changes in glucose parameters. When patients 
who completed the entire 6 month study were analyzed according to their initial monotherapy 
group, adding troglitazone to metformin appreciably increased HDL-C by 7.7% (P=.012). 
Regarding LDL-C, the addition of metformin to troglitazone significantly decreased levels by 
12.4% (P=.009). However, there was no significant overall LDL-C difference with combination 
therapy (-1.6%; P=.66) (Figure 2). 
Combination therapy decreased fasting and postprandial TG by 27.0% (P=.0083), from 
219.7+145.3 to 160.5+117.6 mg/dL (Figure 3) and 15.1% (P=.0059), from 265.2+117.1 to 
225.2+122.6 mg/dL respectively (Figure 4). Fasting and postprandial FFA also appreciably 
decreased. Fasting FFA decreased from .94+.35 to .78+.21 nmol/L (-17.3%; P=.0017) (Figure 5) 
while postprandial FFA decreased from .38+.21 to .18+. 12 (-53.0%; P=2.5E-Q7) (Figure 7). 
Adding troglitazone significantly decreased fasting FFA by 15.4% (P=.Q35) and postprandial 
FFA by 38.14% (P=.0029). These significant changes did not correlate with any changes in the 
glucose parameters. 
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DISCUSSION 
Our study demonstrates that metformin and troglitazone had similar insignificant effects 
on HDL-C. The marginal effect on HDL-C seen with metformin is consistent with the literature. 
However, past studies have demonstrated that troglitazone can appreciably increase HDL-C 
levels in patients with T2DM (45, 46, 51, 55). The reason for the discrepancy between our 
findings and the existing literature is unclear. A plausible explanation may be an insufficient 
sample size of the troglitazone monotherapy group. In fact, not only did HDL-C concentrations 
rise significantly with combination therapy, but also, the addition of troglitazone to the metformin 
monotherapy group appreciably increased HDL-C levels. This suggests that the greater sample 
size found in the combination group may have allowed the effect of troglitazone on HDL-C 
elevation to become statistically evident. The significant effect seen with combination therapy 
also raises the possibility that simultaneous metformin and troglitazone administration may have 
some additive beneficial effects on CVD risk. 
The divergent effects of metformin (55, 59, 60) and troglitazone (71, 74, 75, 78) on LDL- 
C are consistent with past studies. Metformin demonstrated significant LDL-C lowering effect. 
Its effects were significantly better than troglitazone, which marginally elevated LDL-C instead. 
Additionally, metformin and troglitazone administered simultaneously overall had a neutral effect 
on LDL-C. Although LDL-C lowering seen with metformin are noteworthy and may play a 
beneficial role in cardiovascular risk reduction as was implied by the UKPDS (8), the 
implications of LDL-C elevation with troglitazone are less clear. The LDL-C increase may be 
secondary to LDL-C particle size. As was previously mentioned, patients treated with 
troglitazone are noted to have larger, more buoyant LDL-C particles, which may be less 
susceptible to oxidation, and therefore, less atherogenic (77, 78, 81). Because calculated LDL-C 
is affected by both the number and size of the particles, it is difficult to ascertain in this study, 
which component was actually responsible for the elevation in the troglitazone treated group. 
Future studies which measure apoprotein B levels in conjunction with LDL-C levels or directly 
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measure LDL particle size (through ultracentrifugation techniques) will be helpful for 
clarification. 
Metformin and troglitazone had minimal effects on fasting and postprandial TG when 
used alone, but significantly decreased these parameters when used in combination. The 
monotherapy results contradicted existing literature. Most studies demonstrate that both anti- 
hyperglycemics lower overall TG levels, with troglitazone faring somewhat better (46, 47, 49, 50, 
51, 52, 53, 54, 55, 63, 72, 73, 76, 77). TG reduction seen with metformin treatment is attributed 
to decreased hepatic VLDL-C synthesis. Troglitazone, however, is believed to decrease the 
precursors for TG production through insulin sensitization and/or direct anti-lipolytic effects on 
adipocytes. The discrepancy between our monotherapy results and the existing literature may 
again, be attributable to the sample size. The ability of combination therapy to significantly 
reduce fasting and to a lesser magnitude, postprandial TG, is possibly secondary to the larger 
sample size or may again be due to an additive effect achieved with combination therapy. 
Last, this study demonstrated the effects of metformin and troglitazone on fasting and 
postprandial FFA. Troglitazone had significant effects on fasting FFA. Not only did it decrease 
FFA to a significantly greater extent than metformin, but also, the addition of troglitazone to 
metformin monotherapy significantly lowered fasting FFA in this subgroup of patients. 
Combination therapy seemed to offset the degree of reduction seen with troglitazone alone. 
Meanwhile, both metformin and troglitazone significantly decreased postprandial FFA when used 
alone and in combination, postprandial FFA were decreased to a slightly greater extent. These 
results are similar to existing studies. Metformin has yielded inconsistent FFA results (35, 45, 
46) whereas troglitazone has been noted to consistently decrease overall FFA (72, 73). 
Troglitazone works through the nuclear receptor, PPAR, which is predominantly found in adipose 
tissue (69, 70). Therefore, its insulin sensitizing properties may work directly through fat cells by 
decreasing lipolysis, and, therefore, FFA release. Indeed, there was a greater FFA percentage 
change found in the postprandial state, when insulin is more abundant, than in the fasting state. 
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The decrease of fasting FFA in the troglitazone group was the sole parameter found to 
correlate with glucose lowering. The reason is unclear. Perhaps a decrease in glucotoxicity 
facilitated improved FFA metabolism or vice versa. Theoretically, a relationship does exist 
between FFA and glucose through the Randle cycle. There is speculation that medications which 
decrease FFA improve insulin sensitivity, which then facilitates glucose disposal and oxidation in 
muscle and fat, and decreases hepatic glucose production in liver. There was, however, no 
significant correlations found between fasting FFA and glucose production and/or glucose 
disposal. 
This study, which directly compared the effects on lipid metabolism of metformin and 
troglitazone, when used alone and in combination, had limitations. Data was derived from an 
original prospective study that was not designed to analyze changes in lipid metabolism, but 
rather, changes in glucose and FlbAlc. Therefore, the small sample size may not be powered to 
identify all of the significant changes in the lipid parameters. In addition, the lipid profiles of 
patients may have been affected by factors other than the oral anti-hyperglycemic medications. 
Several patients were on anti-lipid medications. However, since these patients had been taking 
anti-lipid medications prior to the study and then continued on a fixed constant dosage throughout 
the study, it was not expected to be a significant confounder. Second, a diet comprised of 50% 
carbohydrate, 34% fat, and 16% protein was recommended to all participants to maintain baseline 
body weight. Although diet does beneficially affect lipid metabolism, all participants were 
encouraged to follow the same diet. In addition, all values were obtained at least 2 weeks after 
diet recommendations were made. This 2 week washout period should have provided sufficient 
time for changes attributable to diet alone to become evident. 
Although a small pool of patients was analyzed, there were several significant findings. 
This study demonstrated that metformin and troglitazone may have comparable anti- 
hyperglycemic effects (64), but have differing effects on lipid metabolism. Metformin, which 
primarily decreases hepatic glucose production, was found to significantly alter LDL-C and 
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postprandial FFA, whereas troglitazone, an insulin sensitizer with effects primarily on adipose 
tissue, appreciably decreased fasting and postprandial FFA. When used in combination, 
metformin and troglitazone demonstrated additive effects, most notably on HDL-C and fasting 
and postprandial TG, and to a much lesser degree, on postprandial FFA. 
The beneficial effects on diabetic dyslipidemia demonstrated by metformin and 
troglitazone, both alone and in combination, are intriguing. These effects may indeed play a 
crucial role in reducing the risk for CVD, which is the major cause of mortality in T2DM 
patients. Additionally, the beneficial effects of troglitazone and possibly other TZDs on FFA (ie. 
improved lipotoxicity) may not only reduce macrovascular complications, but also improve (3 cell 
function. Further larger scale prospective studies are needed to better understand the long-term 
clinical implications of these effects. 
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